US equities
|
MU
$922.46
▲+0.91%
NVDA
$217.74
▼-1.61%
SNDK
$1,366.78
▼-2.61%
AMD
$564.93
▼-1.03%
SPCX
$148.35
▼-2.50%
INTC
$95.94
▼-2.22%
AAPL
$343.02
▲+0.02%
META
$735.04
▼-0.34%
MU
$922.46
▲+0.91%
NVDA
$217.74
▼-1.61%
SNDK
$1,366.78
▼-2.61%
AMD
$564.93
▼-1.03%
SPCX
$148.35
▼-2.50%
INTC
$95.94
▼-2.22%
AAPL
$343.02
▲+0.02%
META
$735.04
▼-0.34%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Dianthus Therapeutics, Inc. - Common Stock
(NQ:
DNTH
)
72.80
-1.97 (-2.63%)
Delayed Quote
Updated: 3:29 PM EDT, Oct 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Dianthus Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Dianthus Therapeutics Recognized Among Fortune’s 2026 Best Workplaces In BioPharma
October 13, 2026
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 01, 2026
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting
September 29, 2026
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 02, 2026
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics to Participate in Three Investor Conferences During September
September 01, 2026
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results
August 04, 2026
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases
August 04, 2026
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
August 03, 2026
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)
July 02, 2026
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis
June 29, 2026
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 02, 2026
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics to Participate in Two Investor Conferences
May 26, 2026
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing
↗
May 18, 2026
Xenon Pharmaceuticals develops therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.
Via
The Motley Fool
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish
↗
May 18, 2026
Specializing in monoclonal antibody therapies, this clinical-stage biotech targets severe autoimmune and inflammatory diseases.
Via
The Motley Fool
Topics
Regulatory Compliance
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally
↗
May 17, 2026
This clinical-stage biotech develops antibody therapies for severe autoimmune diseases, targeting rare neuromuscular conditions.
Via
The Motley Fool
Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120%
↗
May 13, 2026
This biotech specializes in small molecule kinase inhibitors for cancer, with lead drug candidates in early-stage clinical trials.
Via
The Motley Fool
Topics
Regulatory Compliance
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company
↗
May 13, 2026
This clinical-stage biotech develops targeted radiopharmaceutical therapies for cancer using a proprietary miniprotein platform.
Via
The Motley Fool
Topics
Initial Public Offering
Regulatory Compliance
Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally
↗
May 13, 2026
This clinical-stage biotech develops monoclonal antibody therapies targeting psoriasis and other immunology indications.
Via
The Motley Fool
Topics
Regulatory Compliance
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
May 05, 2026
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 01, 2026
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000
↗
April 19, 2026
This clinical-stage biotech focused on monoclonal antibody therapies reported a notable insider sale in its latest SEC filing.
Via
The Motley Fool
Topics
Regulatory Compliance
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 06, 2026
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics CFO Sells $9.5 Million in Stock
↗
April 06, 2026
This biotech firm developing antibody therapies for rare diseases disclosed a significant insider sale amid rapid share price gains.
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit
↗
March 18, 2026
Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.
Via
The Motley Fool
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
March 12, 2026
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Complementing the Future: A Deep Dive into Dianthus Therapeutics (DNTH) After Its Phase 3 Breakthrough
March 12, 2026
Date: March 12, 2026 Introduction Dianthus Therapeutics (NASDAQ: DNTH) has become the center of Wall Street’s attention today, with its share price surging 19.4% in early trading following a pivotal...
Via
Finterra
Topics
Economy
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering
March 10, 2026
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering
March 09, 2026
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch
↗
March 09, 2026
Dianthus Therapeutics announced an early “go” decision for its experimental drug claseprubart in its Chronic Inflammatory Demyelinating Polyneuropathy program based on analysis of data from a part of...
Via
Stocktwits
Gapping stocks in Monday's session
↗
March 09, 2026
Via
Chartmill
< Previous
1
2
3
4
Next >
